the ADBL report

Issue #107, March 2019

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on January 21, 2019. The Committee reviewed Manufacturer submissions for six (6) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of thirteen (13) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, four (4) Drug Products underwent Expedited Review for listing on the *ADBL* effective March 1, 2019.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.html

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective March 1, 2019:

- **ACTEMRA*** (tocilizumab) (HLR) **162 mg/0.9 mL injection syringe** for the indication of Giant Cell Arteritis (GCA) via Special Authorization (SA)
- **IZBA** (travoprost) (NOV) **0.003% ophthalmic solution**
- **LIXIANA*** (edoxaban tosylate monohydrate) (SEV) **15 mg, 30 mg & 60 mg tablets** via Step Therapy/Special Authorization
- **TALTZ*** (ixekizumab) (LIL) **80 mg/mL autoinjector & injection syringe** for the indication of Psoriatic Arthritis (PsA) via SA

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (03/2019)

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of a New IC Grouping, effective March 1, 2019:

- **APO-TRAVOPROST-TIMOP** (travoprost/timolol maleate) (APX) **0.004%/0.5% ophthalmic solution**
- **MAR-DAPSONE** (dapsone) (MAR) **100 mg tablet**

Highlights of Drug Products Added

The following Line Extension Drug Product was reviewed by the Expert Committee and added to the *ADBL* effective March 1, 2019:

- **BASAGLAR KWIKPEN (80 UNITS PER INJECTION DELIVERY)** (insulin glargine) (LIL) **100 unit/mL injection**

Highlights of Changes to Currently Listed Products

The criteria for coverage via Special Authorization were revised for the following Drug Products effective March 1, 2019:

- **ABILIFY MAINTENA*** (aripiprazole) (OTS) **300 mg/vial & 400 mg/vial injections**
- **INVEGA SUSTENNA*** (paliperidone palmitate) (JAI) **50 mg/0.5 mL, 75 mg/0.75 mL, 100 mg/1 mL & 150 mg/1.5 mL injection syringes**
- **INVEGA TRINZA*** (paliperidone palmitate) (JAI) **175 mg/0.875 mL, 263 mg/1.315 mL, 350 mg/1.75 mL & 525 mg/2.625 mL injection syringes**
- **RISPERDAL CONSTA*** (risperidone) (JAI) **25 mg/vial, 37.5 mg/vial & 50 mg/vial injections**

After assessment by the Expert Committee, the listing status of the following Drug Products will be changed from Restricted Benefits to Regular Benefits effective March 1, 2019:

- **MOMETASONE** (mometasone furoate) **50 mcg/dose aqueous nasal sprays** (all brands)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*
ABC 81171 (03/2019)